Amarin Corporation plc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $253.9M
- Price
- $12.02
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.41%
- Volume
- 74.9K
About
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Quick stats
Shares outstanding21.1M
Computed float20.9M
Float / shares99.0%
Key info
SectorHealthcare
IndustryDrug Manufacturers - General
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000897448
Websitehttps://www.amarincorp.com
AI Summary
AI-generated1/15
standardbullishoperations update
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Amarin highlighted new mechanistic and post-hoc data from the REDUCE-IT trial at the ESC Congress 2026, expanding understanding of treatment adherence, lipoprotein(a) biology, and coagulation pathways.
The 2026 ESC/European Renal Association guidelines recognized evidence from REDUCE-IT, adding to the 70+ medical societies globally that support the use of icosapent ethyl for cardiovascular risk reduction.
Mechanistic studies presented indicated that EPA limits rapid oxidation of Lp(a) and reduces tissue factor expression, providing further biological support for the clinical benefits of VASCEPA and VAZKEPA.